Why BPC-157 study amounts don't travel
The units, the species and the route belong together. Removing any of them makes a study figure look deceptively portable.
BPC-157 dosage: experimental amounts
I won't detach a number from the animal that received it. In the rat Achilles-tendon experiment, the amounts were 10 micrograms, 10 nanograms or 10 picograms per rat. The gastric-ulcer experiment used 400 ng/kg and 800 ng/kg in rats. Per rat and per kilogram are different ways of specifying an experimental amount.
The researchers were testing healing in particular injury models. These figures do not establish a human dose, duration or schedule, and the spread of experimental amounts does not identify a personal starting point.
The two-adult intravenous safety pilot reported 10 mg then 20 mg; the bladder pilot reported a single 10 mg intravesical amount. Those were what the studies gave their subjects, using different routes for different questions. The review of the human record calls for rigorous large-scale trials; a pilot's amounts remain experimental rather than an established treatment protocol.
BPC-157 half-life: short in rats and dogs
The 2022 rat-and-dog study reported an elimination half-life of less than 30 minutes. After intramuscular delivery, reported bioavailability was approximately 14-19% in rats and 45-51% in dogs. Bioavailability is the share of an administered amount that reaches the circulation.
The same study traced rapid breakdown into smaller peptide fragments and excretion through urine and bile. I think the rat–dog difference is more useful than a single impressive-looking number: even those two animal populations did not handle the route alike.
Longer-lasting tissue repair in animal experiments is a different observation from how long intact peptide remains in blood. The vascular findings offer a possible mechanism that could outlast exposure; they do not establish a human dosing interval or a human clearance time.
BPC-157 oral research starts with stability, not absorption
Reported stability in human gastric juice explains the interest in oral or intragastric routes. It does not settle how much reaches human blood. The pharmacokinetic paper discusses the gastric-stability rationale, while the rat-ulcer study found greater healing with intramuscular than intragastric delivery.
The word stable is doing a smaller job here than an oral-treatment claim requires. I accept it as a reason to test the route; a result in people still requires that test. Formal human oral pharmacokinetics and controlled human oral efficacy are not established in this record.
Animal routes included delivery into the abdominal cavity, muscle and stomach, as well as local delivery. Human pilot routes included a vein, the bladder and a knee joint. The research page explains the outcome each human report actually pursued. None supplies instructions for handling or using the compound.